Ann Liver Transplant.  2024 May;4(1):16-22. 10.52604/alt.24.0004.

Carbapenem-resistant gram-negative rod bacteremia in the early postoperative period following liver transplantation

• Min EK
• Kim DG
• Kang M
• Koh HH
• Lee JG
• Joo DJ
• Kim MS

• KMID: 2560937
• DOI: http://doi.org/10.52604/alt.24.0004

Abstract

Background
Carbapenem-resistant gram-negative rod bacteremia (CRGNR-B) is emerging as a formidable challenge, complicating patient management and outcomes in liver transplantation (LT). This study aimed to investigate the incidence, mortality, and risk factors associated with CRGNR-B within 90 days following LT.
Methods
A retrospective nested case-control study was conducted using single centric LT data (n=1,379). CRGNR-B cases were matched 1:5 with control patients for analyzing survival and risk factors for CRGNR-B.
Results
The incidence of CRGNR-B within 90 days post-LT was 6.5% (n=87). The CRGNR-B group showed significantly lower 1-year post-LT survival compared to the control group (37.9% vs. 90.0%, p<0.001). CRGNR-B was significantly correlated with increased mortality after adjustment of covariates (adjusted hazard ratio, 5.66; 95% confidence interval [CI], 3.89–8.24; p<0.001). Key risk factors identified include higher pretransplant model for end-stage liver disease scores (odds ratio [OR], 1.05; 95% CI, 1.01–1.09; p=0.006), encephalopathy prior to transplant (OR, 2.79; 95% CI, 1.48–5.30; p=0.002), retransplantation (OR, 10.4; 95% CI, 2.79–42.1; p<0.001), each 60-minute increase in cold ischemic time (OR, 1.20; 95% CI, 1.01–1.42; p=0.037), and bile duct complications (OR, 6.16; 95% CI, 2.66–14.2; p<0.001).
Conclusion
The occurrence of CRGNR-B within 90 days post-LT poses a significant risk to patient survival, with identifiable pre- and peri-transplant risk factors. These findings underscore the importance of targeted preventive measures, early detection, and effective management strategies to enhance outcomes for LT recipients.

Keyword

Carbapenem resistant; Gram negative; Liver transplantation

Figure

• 

  Figure 1 Study flow for nested case-control study. LT, liver transplantation; CRGNR-B, carbapenem-resistant gram-negative rod bacteremia.

• 

  Figure 2 Cumulative incidence of carbapenem-resistant gram-negative rod bacteremia (CRGNR-B) wihtin 90 days after liver transplantation (LT).

• 

  Figure 3 Kaplan-Meier curves for graft survival after index date. CRGNR-B, carbapenem-resistant gram-negative rod bacteremia; POD, postoperative day.

Reference

1. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. 2012; Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 57:675–688. DOI: 10.1016/j.jhep.2012.04.015. PMID: 22609307.

2. Zhang J, He Q, Du L, Ji R, Yuan L, Zhang H, et al. 2021; Risk factor for lung infection in recipients after liver transplantation: a meta-analysis. Artif Organs. 45:289–296. DOI: 10.1111/aor.13826. PMID: 32979870.

3. Kim SI. 2014; Bacterial infection after liver transplantation. World J Gastroenterol. 20:6211–6220. DOI: 10.3748/wjg.v20.i20.6211. PMID: 24876741. PMCID: PMC4033458.

4. Krell RW, Kaul DR, Martin AR, Englesbe MJ, Sonnenday CJ, Cai S, et al. 2013; Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl. 19:1396–1402. DOI: 10.1002/lt.23752. PMID: 24151041. PMCID: PMC3870151.

5. Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. 2011; The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation. 91:1240–1244. DOI: 10.1097/TP.0b013e31821841ba. PMID: 21516069.

6. Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, et al. 2017; Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group. Transplantation. 101(4S Suppl 2):S1–S56. DOI: 10.1097/TP.0000000000001651. PMID: 28328734.

7. Ye QF, Zhao J, Wan QQ, Qiao BB, Zhou JD. 2014; Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality. Transpl Infect Dis. 16:767–774. DOI: 10.1111/tid.12278. PMID: 25124187.

8. Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, Roca J, et al. 2013; Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 96:843–849. DOI: 10.1097/TP.0b013e3182a049fd. PMID: 23883973.

9. Zhong L, Men TY, Li H, Peng ZH, Gu Y, Ding X, et al. 2012; Multidrug-resistant gram-negative bacterial infections after liver transplantation - spectrum and risk factors. J Infect. 64:299–310. DOI: 10.1016/j.jinf.2011.12.005. PMID: 22198738.

10. Martin-Mateos R, Martínez-Arenas L, Carvalho-Gomes Á, Aceituno L, Cadahía V, Salcedo MM, et al. Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors. J Hepatol. 2024; https://doi.org/10.1016/j.jhep.2024.02.023 [Epub ahead of print]. DOI: 10.1016/j.jhep.2024.02.023. PMID: 38428641.

11. Gao S, Huang X, Zhou X, Dai X, Han J, Chen Y, et al. 2024; A comprehensive evaluation of risk factors for mortality, infection and colonization associated with CRGNB in adult solid organ transplant recipients: a systematic review and meta-analysis. Ann Med. 56:2314236. DOI: 10.1080/07853890.2024.2314236. PMID: 38442299. PMCID: PMC10916923.

12. Freire MP, Oshiro IC, Pierrotti LC, Bonazzi PR, de Oliveira LM, Song AT, et al. 2017; Carbapenem-resistant Enterobacteriaceae acquired before liver transplantation: impact on recipient outcomes. Transplantation. 101:811–820. DOI: 10.1097/TP.0000000000001620. PMID: 28009779. PMCID: PMC7228606.

13. Min EK, Yim SH, Choi MC, Lee JG, Joo DJ, Kim MS, et al. 2023; Incidence, mortality, and risk factors associated with carbapenem-resistant Acinetobacter baumannii bacteremia within 30 days after liver transplantation. Clin Transplant. 37:e14956. DOI: 10.1111/ctr.14956. PMID: 36860160.

14. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, et al. 2013; Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 13:2619–2633. DOI: 10.1111/ajt.12424. PMID: 24011185. PMCID: PMC3955300.

15. Freire MP, Pierrotti LC, Oshiro IC, Bonazzi PR, Oliveira LM, Machado AS, et al. 2016; Carbapenem-resistant Acinetobacter baumannii acquired before liver transplantation: impact on recipient outcomes. Liver Transpl. 22:615–626. DOI: 10.1002/lt.24389. PMID: 26684547.

16. Smith ZL, Oh YS, Saeian K, Edmiston CE Jr, Khan AH, Massey BT, et al. 2015; Transmission of carbapenem-resistant Enterobacteriaceae during ERCP: time to revisit the current reprocessing guidelines. Gastrointest Endosc. 81:1041–1045. DOI: 10.1016/j.gie.2014.11.006. PMID: 25638508.

17. Doi Y. 2019; Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 69(Suppl 7):S565–S575. DOI: 10.1093/cid/ciz830. PMID: 31724043. PMCID: PMC6853760.

18. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. 2021; Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 21:226–240. DOI: 10.1016/S1473-3099(20)30796-9. PMID: 33058795.